Iterum Therapeutics (ITRMF) Q3 2025 Earnings Report

The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.

In the third quarter of 2025, Iterum Therapeutics reported net product sales of $400,000 with the launch of Orlynda in the U.S. in August 2025. The company successfully generated over 280 prescriptions through more than 100 unique prescribers, indicating growing physician and patient engagement. Approximately 40% of prescriptions have been filled through payer approval processes, aligning with expectations despite awaiting broader payer coverage. Iterum anticipates 2026 net product revenue to range between $5 million and $15 million, supported by expanding insurance coverage, particularly with a recent signed rebate agreement with a top Medicare Part D pharmacy benefit manager. Operating expenses for 2026 are projected between $25 million and $30 million, with current cash reserves expected to fund operations into 2026. The company aims to raise additional capital to sustain commercialization efforts, targeting high-value territories and potentially expanding further.